Next, the overall survival (OS) and progression‐free survival (PFS) rates were lower in BLCA patients with upregulated PGK1 compared to those with downregulated PGK1 (Figure 2A). This evidence concerns the gene PGK1 and bladder transitional cell carcinoma.